Here's Why Incyte (INCY) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • 4 hours ago

Incyte: I Am Moving From Hold To Buy

Incyte is upgraded to Buy as pipeline progress and improved EPS estimates offset Jakafi concentration risk. frontMIND Phase 3 data for Monjuvi in first-line DLBCL is promising, supporting potential market share gains despite emerging competition. INCY acquired Vega Therapeutics, adding VGA039 to its hematology portfolio.

Seeking Alpha • Jun 10, 2026

Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster Potential

Incyte Corporation (NASDAQ:INCY) said Monday it has agreed to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, in a deal valued at $1.25 billion upfront.

Benzinga • Jun 9, 2026

Incyte Corporation (INCY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Incyte Corporation (INCY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • Jun 9, 2026

Incyte to Buy Vega Therapeutics in Hematology Deal Worth Up to $2B

Incyte will acquire Vega Therapeutics for up to $2B, adding late-stage VWD candidate VGA039 and expanding its hematology growth prospects.

Zacks Investment Research • Jun 9, 2026

Incyte strikes up to $2 billion deal for Star Therapeutics' subsidiary

Incyte said ​on Monday ‌it has agreed ​to ​acquire Vega Therapeutics, ⁠a wholly ​owned ​subsidiary of Star Therapeutics, in ​a ​deal worth up ‌to $2 ⁠billion, expanding its pipeline ​for ​blood ⁠disorder therapies.

Reuters • Jun 8, 2026

Incyte to Buy Vega Therapeutics For Up to $2 Billion

Incyte has agreed to buy Vega Therapeutics for up to $2 billion in a deal that expands the biopharmaceutical company's hematology portfolio into bleeding disorders.

WSJ • Jun 8, 2026

Incyte Corporation (INCY) M&A Call Transcript

Incyte Corporation (INCY) M&A Call Transcript

Seeking Alpha • Jun 8, 2026

Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders.

Business Wire • Jun 8, 2026

Here's Why Incyte (INCY) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Jun 8, 2026